Market Cap
$250,616,776,074
Enterprise Value
$272,659,776,074
Average Volume
$13,188,457
Merck & Co., Inc. - MRK
$99.72
-1.17
(-1.16%)
Valuation & Solvency
P/Tangible Book
4.80
P/E
13.09
P/S
3.90
EV/EBITDA
10.42
EV/Sales
4.24
EV/FCF
20.90
Dividend Yield
3.25%
Payout Ratio
42.60%
Total Debt
$41,374,000,000
Cash & Marketable Securities
$18,214,000,000
Quick Ratio
1.44
Debt/Equity
0.80
Net Debt/EBITDA
0.84
Interest Coverage Ratio
19.76
About
Industry
Drug Manufacturers - General
Exchange
NYSE
Country
US
Beta
0.30
Company Description
▶
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.